要文快报！华尔街风云：CPI数据抢占头条，美联储决议紧随其后，AI浪潮势不可挡

华尔街风云：CPI数据抢占头条，美联储决议紧随其后，AI浪潮势不可挡

2024年6月13日，华尔街迎来关键的“超级星期三”，两大重要事件接踵而至：美国劳工统计局发布5月消费者价格指数（CPI）数据，以及美联储联邦公开市场委员会（FOMC）公布利率决议。这两大事件将对全球金融市场产生深远影响。

CPI数据备受关注，通胀压力仍是焦点

5月CPI数据是衡量美国通胀水平的关键指标，也是美联储制定货币政策的重要依据。市场预计5月CPI同比增长将有所回落，但仍将维持在高位。如果CPI数据超预期，表明通胀压力依然严峻，美联储可能继续采取加息措施，以抑制通胀。这将对股市、债券和其它金融资产价格造成压力。

美联储决议料将加息，抗通胀决心坚定

美联储FOMC将于6月13日至14日召开货币政策会议，并于15日公布决议。市场普遍预计美联储将在此次会议上加息50个基点，以遏制通胀。美联储主席鲍威尔 неоднократно表示，抗击通胀是美联储的首要任务，即使经济放缓，也需要采取必要的措施。

AI浪潮势不可挡，科技创新驱动经济增长

除了宏观经济事件，科技创新也是本周关注的焦点。人工智能（AI）技术发展迅猛，正在各个领域掀起变革浪潮。AI公司持续发布新产品、新服务，不断拓展应用场景，为经济增长注入新的活力。投资者密切关注AI领域的最新进展，寻找投资机会。

总体而言，本周华尔街将迎来一系列重磅事件，投资者需谨慎应对市场波动。CPI数据和美联储决议将指引市场走向，而AI浪潮也将继续推动科技创新和经济发展。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.